This new imaging technique more accurately detects lymph node metastases that are too small to be seen using conventional means. This method, which combines MRI (high-resolution magnetic resonance image) and lymphotrophic superparamagnetic nanoparticles, has increased the sensitivity of MRI screening of prostate cancer lymph node metastases from 45% to nearly 100%. This technique is currently undergoing evaluation by the FDA for clinical use. This is also called Combidex.